Envoy Medical Statistics
Total Valuation
Envoy Medical has a market cap or net worth of $53.94 million. The enterprise value is $40.15 million.
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Envoy Medical has 7.74 million shares outstanding. The number of shares has increased by 264.88% in one year.
| Current Share Class | 7.74M |
| Shares Outstanding | 7.74M |
| Shares Change (YoY) | +264.88% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 30.73% |
| Owned by Institutions (%) | 13.00% |
| Float | 4.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 231.33 |
| Forward PS | 138.80 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 171.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.21
| Current Ratio | 1.21 |
| Quick Ratio | 1.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -108.38% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -484.92% |
| Weighted Average Cost of Capital (WACC) | 15.12% |
| Revenue Per Employee | $4,915 |
| Profits Per Employee | -$552,128 |
| Employee Count | 47 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.28% in the last 52 weeks. The beta is 2.02, so Envoy Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.02 |
| 52-Week Price Change | +4.28% |
| 50-Day Moving Average | 6.79 |
| 200-Day Moving Average | 6.88 |
| Relative Strength Index (RSI) | 55.17 |
| Average Volume (20 Days) | 36,431 |
Short Selling Information
The latest short interest is 89,915, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 89,915 |
| Short Previous Month | 577,087 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 4.48 |
Income Statement
In the last 12 months, Envoy Medical had revenue of $231,000 and -$25.95 million in losses. Loss per share was -$3.39.
| Revenue | 231,000 |
| Gross Profit | -625,000 |
| Operating Income | -23.70M |
| Pretax Income | -20.85M |
| Net Income | -25.95M |
| EBITDA | -23.40M |
| EBIT | -23.70M |
| Loss Per Share | -$3.39 |
Full Income Statement Balance Sheet
The company has $14.57 million in cash and $777,000 in debt, with a net cash position of $13.79 million or $1.78 per share.
| Cash & Cash Equivalents | 14.57M |
| Total Debt | 777,000 |
| Net Cash | 13.79M |
| Net Cash Per Share | $1.78 |
| Equity (Book Value) | -1.14M |
| Book Value Per Share | -0.15 |
| Working Capital | 2.99M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$22.23 million and capital expenditures -$205,000, giving a free cash flow of -$22.44 million.
| Operating Cash Flow | -22.23M |
| Capital Expenditures | -205,000 |
| Depreciation & Amortization | 302,000 |
| Net Borrowing | -763,000 |
| Free Cash Flow | -22.44M |
| FCF Per Share | -$2.90 |
Full Cash Flow Statement Margins
| Gross Margin | -270.56% |
| Operating Margin | -10,261.04% |
| Pretax Margin | -9,026.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Envoy Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -264.88% |
| Shareholder Yield | -264.88% |
| Earnings Yield | -48.67% |
| FCF Yield | -41.99% |
Analyst Forecast
The average price target for Envoy Medical is $19.67, which is 182.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.67 |
| Price Target Difference | 182.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 231.13% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on October 26, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Envoy Medical has an Altman Z-Score of -26.88 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -26.88 |
| Piotroski F-Score | 3 |